• Biosimilars
  • Drug Development/R&D
  • All Topics
OHE OHE
Newsletter SignupSubscribe

News & Insights
  • News
  • Events
  • Insights
  • Bulletin
  • News
  • Events
  • Insights
  • Bulletin

News & Insights

  • News
  • Events
  • Insights
  • Bulletin
Newsletter SignupSubscribe
  • News
  • Events
  • Insights
  • Bulletin

Close
OHE OHE
  • Research & Publications
  • News & Insights
  • Education
  • Innovation Policy Prize
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe

Research & Publications

All Publications

Filter by:
  • Antimicrobial Resistance (AMR)
  • Biosimilars
  • Cell and Gene Therapies
  • Chronic Diseases
  • Combination Therapies
  • COVID-19 Research
  • Digital Health
  • Drug Development/R&D
  • Emerging Markets
  • EQ-5D and PROMs
  • Health Care Systems
  • Health Data and Statistics
  • Health Technology Assessment
  • Precision Medicine
  • Real World Evidence
  • Use of Medicines
  • Value-Based Pricing
  • Vaccine Research
  • Economics of Innovation
  • Measuring and Valuing Outcomes
  • Policy, Organisation and Incentives in Health Systems
  • Value, Affordability and Decision Making

News & Insights

  • News
  • Events
  • Insights
  • Bulletin

Education

  • Education Hub
  • OHE Graduate School
  • EVIA Programme

Innovation Policy Prize

  • The Prize Fund
  • 2022 Prize Fund

Latest Research & Publications

  • Antimicrobial Resistance (AMR)
  • Economics of Innovation

Incentivising New Antibiotics: Designing a Value-Based Delinked Pull Incentive Mechansim

Men rowing on a river
Read more

Proposal for a General Outcome-based Value Attribution Framework for Combination Therapies

CombTher_Adobe_photoguns_portrait
Read more
© photoguns
  • Digital Health

Navigating the Landscape of Digital Health – United Kingdom

Healthcare_Adobe_elenabsl
Read more

2021 OHE Annual Report to the Charity Commission

charityreport_lina-trochez-unsplash_landscape
Read more
© Lina Trochez/Unsplash

Supporting the Era of Green Pharmaceuticals in the UK

Sustainability_AdobeStock_270582392_landscape
Read more

Quality of life and wellbeing in individuals with experience of fertility problems and assisted reproductive techniques

Quality of life assisted reproduction Cover
Read more
  • Cell and Gene Therapies
  • Value, Affordability, and…

Health Technology Assessment of Gene Therapies: Are Our Methods Fit for Purpose?

gene_therapies_national-cancer-institute-unsplash_landscape
Read more
© NCI/Unsplash
  • Drug Development/R&D
  • Economics of Innovation
  • Health Policy and Regulation

Limitations of CBO’s Simulation Model of New Drug Development as a Tool for Policymakers

CBO-US_mayer-tawfik-K4Ckc0AxgDI-unsplash_landscape
Read more
© Mayer Tawfik/Unsplash
Close
OHE
  • All Publications

    Filter by:
    • Antimicrobial Resistance (AMR)
    • Biosimilars
    • Cell and Gene Therapies
    • Chronic Diseases
    • Combination Therapies
    • COVID-19 Research
    • Digital Health
    • Drug Development/R&D
    • Emerging Markets
    • EQ-5D and PROMs
    • Health Care Systems
    • Health Data and Statistics
    • Health Technology Assessment
    • Precision Medicine
    • Real World Evidence
    • Use of Medicines
    • Value-Based Pricing
    • Vaccine Research
    • Economics of Innovation
    • Measuring and Valuing Outcomes
    • Policy, Organisation and Incentives in Health Systems
    • Value, Affordability and Decision Making
    • News
    • Events
    • Insights
    • Bulletin
    • Education Hub
    • OHE Graduate School
    • EVIA Programme
    • The Prize Fund
    • 2022 Prize Fund
  • Events
  • About Us
  • OHE Experts
  • Contact Us
Newsletter SignupSubscribe
Back
  • News
11 min read 29th July 2015

An Issues Panel: Developing Cost Effectiveness for Decision Making: What can be Learnt from “Value Based Pricing”?

This post reports on an Issues Panel which was held at the Spanish Health Economics Association Annual Conference which took place in Granada, Spain 17-19 June 2015. The title of the panel was: Developing cost effectiveness for decision making: what…

Share:
  •  Twitter
  •  LinkedIn
  •  Facebook
  • has-icon Email

This post reports on an Issues Panel which was held at the Spanish Health Economics Association Annual Conference which took place in Granada, Spain 17-19 June 2015. The title of the panel was: Developing cost effectiveness for decision making: what can be learnt from “Value Based Pricing”?

OHE members presented in several sessions at the Spanish Health Economics Association Annual Conference which took place in Granada, Spain 17-19 June 2015. This post focuses on an Issues Panel entitled “Developing cost effectiveness for decision making: what can be learnt from “Value Based Pricing”?” which included a contribution from Adrian Towse, Director of the OHE.

The panel was organised and chaired by Allan Wailoo, Professor of Health Economics and Director of the NICE Decision Support Unit, University of Sheffield. It included the following contributions:

Adrian Towse presented “Reflections on Value Based Pricing/Assessment” with an overview of the main elements of the Value Based Pricing (VBP) proposals. These included: 

  • The impact of the 2007 Office of Fair Trading Report’s arguments for the introduction of risk-sharing/coverage with evidence development arrangements as part of VBP, which led to the introduction of Patient Access Schemes in the 2009 PPRS. 
  • The question of whether NICE and/or the Department of Health (DH) should be a price taker or a price setter. 
  • A review of the survey evidence collected by the Policy Research Unit in Economic Evaluation of Health and Care Interventions (EEPRU) as part of the DH VBP exercise on public preferences for elements of value including innovation and “end of life” adjustments. 

He concluded that: 

  • Work on the broader definition of value needs to continue. It requires better understanding of the preferences of the public and of patients. There was a need to invest in preference elicitation.
  • Price flexibility by indication/subgroup and outcomes-based CED/PBRSA schemes are important for getting dynamic and static efficiency from the use of drugs. Reform of the CDF offers a way forward to try more of these approaches 
  • A deliberative process is necessary in value assessment. Introducing structure to this process (MCDA) is a challenge.

Reflections_on_VBP_AKT_June2015 from Office of Health Economics
 
Gavin Roberts PhD, Economic Advisor at the Department of Health outlined a “Methodology for estimating the wider economic impacts of health conditions and treatments”. 

He described a methodology, developed as part of the VBP process, which was designed to provide substantially complete estimates of the value of “wider” economic impacts for any condition, treatment or programme, using routinely available data. Whilst the impacts of health interventions on the wellbeing of patients can be estimated with instruments such as the quality adjusted life year (QALY).  Changes in an individual’s health state can, however, also have consequential economic impacts on others.  For example, patients who receive treatment may return to work, contributing more in taxation, requiring less welfare benefit or improving family finances – or they may contribute more to looking after family members or providing domestic work.  Changes in health may also mean patients need different amounts of formal or informal social care, as well as other resources of everyday life.

He presented estimates of the value of these impacts for representative treatments, and showed that these vary widely.  In combination with a set of reference estimates, the methodology can be used to calculate the value of economic impacts associated with activity at the margin in the UK NHS producing a figure of 93p per £, i.e. the marginal £1 of NHS expenditure delivers both health gain and wider economic impacts of 93p.

Wider_economic_impacts_of_health_treatments from Office of Health Economics

James Raftery, PhD, Professor of HTA at the University of Southampton, presented on “Value based pricing in UK: a personal view of strengths, weaknesses and risks. (Or why it went wrong.)”

He recapped the history of the development of VBP from the 2007 Office of Fair Trading report recommending the Prescription Pricing Regulation Scheme (PPRS) be replaced by VBP for all branded drugs, through to NICE consulting the public on a QALY shortfall (absolute & relative) proposal in 2014 with the decision, based on the consultation results, to implement no change for the time being. Key challenges included:

  • Political change with a new Government, an ambitious but untested minister and keen interest from several pressure groups
  • An ambiguous mission and title, presented in specialist language, including self-contradicting claims
  • A clash of values between those of the market and the “National Health Service”
  • Un-anticipated consequences, belatedly recognised. 

He noted that NICE’s Public Health Programme had quietly made changes to its methods which were similar to those proposed under VBP. These included a shift to a societal perspective. The lack of controversy with these indicated how the factors listed above affected VBP. 

He put the lessons from VBP and the Lansley NHS reforms in the context of the “The Blunders of our Governments” King & Crewe (2013), which reviewed several major policy blunders up to 2010 including the: introduction of the Poll Tax; running of the Child Support Agency, commissioning of The Millennium Dome; administration of tax credits; Public Private Partnership to fund investment for the London Underground; plans for ID cards; and the programme for NHS IT systems.
 

VBP_in_UK_strengths_weakness from Office of Health Economics

 

  • Health Technology Assessment…
  • Value, Affordability, and…
  • Presentations

Related News

  • News
  • March 2020

How do we Get and Pay for New Antibiotics? Proposed New Models for Value Assessment and Contracting for Payment.

Read more
  • News
  • March 2020

Price Transparency: Good or Bad? What Does Literature and Theory Tell Us?

Read more
  • News
  • January 2020

Funding Challenges in the Malaysian Health Care System

Read more
  • News
  • January 2020

OHE at HESG Winter 2020

Read more
footer_ohe_logo

Leading intellectual authority on global health economics

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

Research & Publications

News & Insights

Innovation Policy Prize

Education

Events

About Us

OHE Experts

Contact Us

Sign Up for the OHE News Bulletin

Newsletter SignupStart Sign Up

The Office of Health Economics (OHE) is a company limited by guarantee registered in England and Wales (registered number 09848965) and its registered office is at 2nd Floor Goldings House, Hay’s Galleria, 2 Hay’s Lane, London, SE1 2HB.

Terms & Conditions

Privacy Policy

Cookies Policy

© 2023 Website Design

An error has occurred, please try again later.An error has occurred, please try again later.

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

 Twitter
 Facebook
 LinkedIn
 Copy
 Email
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!